99 related articles for article (PubMed ID: 26645570)
21. Thiosemicarbazone Cu(II) and Zn(II) complexes as potential anticancer agents: syntheses, crystal structure, DNA cleavage, cytotoxicity and apoptosis induction activity.
Shao J; Ma ZY; Li A; Liu YH; Xie CZ; Qiang ZY; Xu JY
J Inorg Biochem; 2014 Jul; 136():13-23. PubMed ID: 24690556
[TBL] [Abstract][Full Text] [Related]
22. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, anticancer activity and mechanism of iron chelator derived from 2,6-diacetylpyridine bis(acylhydrazones).
Yao Q; Qi J; Zheng Y; Qian K; Wei L; Maimaitiyiming M; Cheng Z; Wang Y
J Inorg Biochem; 2019 Apr; 193():1-8. PubMed ID: 30654208
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.
Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
J Med Chem; 2007 Nov; 50(24):6212-25. PubMed ID: 17963372
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of four binuclear copper(II) complexes: Structure, anticancer properties and anticancer mechanism.
Qi J; Liang S; Gou Y; Zhang Z; Zhou Z; Yang F; Liang H
Eur J Med Chem; 2015; 96():360-8. PubMed ID: 25899339
[TBL] [Abstract][Full Text] [Related]
26. Kinetico-mechanistic studies on methemoglobin generation by biologically active thiosemicarbazone iron(III) complexes.
Basha MT; Bordini J; Richardson DR; Martinez M; Bernhardt PV
J Inorg Biochem; 2016 Sep; 162():326-333. PubMed ID: 27079328
[TBL] [Abstract][Full Text] [Related]
27. 2-Acetylpyridine thiosemicarbazones. 6.2-Acetylpyridine and 2-butyrylpyridine thiosemicarbazones as antileukemic agents.
Klayman DL; Scovill JP; Mason CJ; Bartosevich JF; Bruce J; Lin AJ
Arzneimittelforschung; 1983; 33(7):909-12. PubMed ID: 6684928
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of novel 4-(2-fluorophenoxy)-2-(1H-tetrazol-1-yl)pyridines bearing semicarbazone moieties as potent antitumor agents.
Qin M; Liao W; Xu C; Fu B; Ren J; Gu Y; Gong P
Arch Pharm (Weinheim); 2013 Nov; 346(11):840-50. PubMed ID: 24114959
[TBL] [Abstract][Full Text] [Related]
29. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
30. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer.
Kovacevic Z; Chikhani S; Lovejoy DB; Richardson DR
Mol Pharmacol; 2011 Oct; 80(4):598-609. PubMed ID: 21719465
[TBL] [Abstract][Full Text] [Related]
31. Selenosemicarbazone Metal Complexes as Potential Metal-based Drugs.
Rostán S; Mahler G; Otero L
Curr Med Chem; 2023; 30(5):558-572. PubMed ID: 34951353
[TBL] [Abstract][Full Text] [Related]
32. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
33. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents.
Kwok JC; Richardson DR
Mol Pharmacol; 2004 Jan; 65(1):181-95. PubMed ID: 14722250
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-targeting copper bis(selenosemicarbazone) complexes: comparison with their sulfur analogues.
Castle TC; Maurer RI; Sowrey FE; Went MJ; Reynolds CA; McInnes EJ; Blower PJ
J Am Chem Soc; 2003 Aug; 125(33):10040-9. PubMed ID: 12914467
[TBL] [Abstract][Full Text] [Related]
35. Tumor cell cytotoxicity of a novel metal chelator.
Torti SV; Torti FM; Whitman SP; Brechbiel MW; Park G; Planalp RP
Blood; 1998 Aug; 92(4):1384-9. PubMed ID: 9694727
[TBL] [Abstract][Full Text] [Related]
36. Organometallic osmium arene complexes with potent cancer cell cytotoxicity.
Fu Y; Habtemariam A; Pizarro AM; van Rijt SH; Healey DJ; Cooper PA; Shnyder SD; Clarkson GJ; Sadler PJ
J Med Chem; 2010 Nov; 53(22):8192-6. PubMed ID: 20977192
[TBL] [Abstract][Full Text] [Related]
37. Lysosomal iron, iron chelation, and cell death.
Terman A; Kurz T
Antioxid Redox Signal; 2013 Mar; 18(8):888-98. PubMed ID: 22909065
[TBL] [Abstract][Full Text] [Related]
38. Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism.
Merlot AM; Pantarat N; Menezes SV; Sahni S; Richardson DR; Kalinowski DS
Mol Pharmacol; 2013 Dec; 84(6):911-24. PubMed ID: 24085840
[TBL] [Abstract][Full Text] [Related]
39. Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase.
Kowol CR; Berger R; Eichinger R; Roller A; Jakupec MA; Schmidt PP; Arion VB; Keppler BK
J Med Chem; 2007 Mar; 50(6):1254-65. PubMed ID: 17315858
[TBL] [Abstract][Full Text] [Related]
40. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.
Bernhardt PV; Sharpe PC; Islam M; Lovejoy DB; Kalinowski DS; Richardson DR
J Med Chem; 2009 Jan; 52(2):407-15. PubMed ID: 19090766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
